The previous earnings report from Verastem (VSTM) was filled with volatility and surprises. As I outlined in my last piece, Verastem's Earnings - Is It a Buy Now?, Verastem is a company filled with questions, opportunity, and potential catalysts, however none of these were addressed in the second quarter of 2019, in fact, the loss of President and CEO Robert Forrester makes things even more bleak, which is rather disappointing. Here, I will discuss my thoughts on Verastem going into their earnings report and an update on their commercialization efforts of Copiktra . . .
About Chris Stang
As a young investor, I focus developing biotech companies. I focus strongly on fundamentals, digging deeper to understand the financial and regulatory position of companies. The biotechnology sector is very volatile, please use caution and do your own additional due diligence before investing. I also secondarily focus on small security and defense companies that provide long-term growth opportunities.